Sign Up
cache/87d813f5664d06f9584de17d955f42395dab83f43b28055809f8d73c0c8454ae

DE:AMAPHARM

Amapharm

  • Privately Held
OverviewAnalysisMetricsFinancialsFilingspeopleAPIData
Pros and Cons

Strong financial growth with total assets increasing from €32.8M in 2018 to €63.8M in 2022

Specialization in vitamin gummies, a growing segment in the nutraceutical industry

Diversified product offerings including private label manufacturing and custom formulation services

Consistent increase in equity, suggesting profitable operations

Operating in a high-growth industry with a projected CAGR of 14.4% from 2024 to 2031

Potential regulatory challenges across different markets

Increasing competition in the gummy supplements market

Dependency on consumer perceptions of efficacy and value

Limited information on market share and competitive positioning

Potential challenges in maintaining product stability and efficacy in gummy format

Summary
Competition
The gummy supplements market is highly competitive with a projected growth to $72.17 billion by 2031. Key success factors include product innovation, quality control, regulatory compliance, and effective marketing. Amapharm faces competition from both established supplement companies expanding into gummies and new entrants specializing in this format. The company's focus on children's and adult vitamin gummies, along with private label offerings, may provide a competitive edge, but specific market share data is not available.
Business
Amapharm is a German-based nutraceutical company specializing in the development and production of innovative nutritional supplements, particularly vitamin gummies. Founded in Germany, the company has shown consistent growth, expanding its operations and product portfolio. Amapharm's business model includes both manufacturing its own branded products and offering private label and custom formulation services to other companies in the health and wellness sector.
Recent Acquisitions
Assessment

Growth

Revenue Organic

Consistent growth in assets and equity over the years suggests strong organic revenue growth.

Revenue Overall

Total assets grew from €32.8M in 2018 to €63.8M in 2022, indicating robust overall revenue growth.

Profile

Multinational

Operations in Germany and likely other markets, but specific global presence details are limited.

Clear Market Leader

-

Insufficient information to determine market leadership position.

Buy-and-Build Platform

Limited information on acquisitions; growth seems primarily organic.

Resilience

Non-cyclical

Nutritional supplements industry tends to be resilient to economic cycles, with steady demand for health products.

Revenue Visibility

Consistent growth in revenue over the years indicates good visibility, but specific long-term contracts or recurring revenue streams are not mentioned.

Profitability

Gross Margin

-

Gross margin figures not available in the provided financial data.

EBITDA Margin

-

EBITDA figures not provided in the financial information.

Cash Conversion

Strong cash position growing from €15.3M in 2018 to €10.4M in 2022, indicating good cash conversion.